EVM14 Combined With Ivonescimab in Patients With Squamous Non-Small Cell Lung Cancer

Phase 1, open-label, single-arm trial of EVM14 in squamous cell carcinoma of the lung (SCCL), sponsored by Everest Medicines. Primary endpoints: Incidence of dose-limiting toxicity at 21 days and Incidence and severity of TEAE, TRAE, SAEs, and adverse events (AEs) of Grade ≥ 3. Planned start Nov 2026; status: not yet recruiting.